medigraphic.com
Colegio de Medicina Interna de México.

2022, Number 5

<< Back Next >>

Med Int Mex 2022; 38 (5)

Bone marrow fibrosis associated to metastatic pulmonary adenocarcinoma

Cruz-Castillo C, Sánchez-Ambrocio HB, Díaz-Sánchez AJ, Escobar-España A

Language: Spanish
References: 19
Page: 1100-1106
PDF size: 224.97 Kb.


ABSTRACT

Background: Bone marrow fibrosis is characterized by increased deposition of reticulin fibers and, in some cases, collagen fibers. There is a series of hematological and non-hematological disorders that are associated with an increase in bone marrow fibrosis. Non-small cell lung cancer represents 85% of all cases of lung cancer. Bone metastasis is one of the most common complications among lung cancer survivors. Some patients with bone metastases may suffer pathological fracture, compression of the spinal cord or malignant hypercalcemia.
Clinical case: A 57-year-old male patient with a history of diabetes mellitus and smoking, who presented with a clinical picture of low back pain of 4 months of evolution; at admission he had hypercalcemia, acute kidney injury, anemia and osteolytic lesions. A diagnostic approach of hypercalcemia of neoplastic origin was made.
Conclusions: The approach of a patient with high suspicion of multiple myeloma was carried out, without being able to establish that diagnosis, for which reason an iliac crest biopsy and tomographic study were requested, documenting bone marrow fibrosis associated with metastatic pulmonary adenocarcinoma.


REFERENCES

  1. Zahr AA, Salama ME, Carreau N, Tremblay D, VerstovsekS, Mesa R, et al. Bone marrow fibrosis in myelofibrosis:Pathogenesis, prognosis and targeted strategies. Haematologica 2016; 101 (6): 660-71. doi: 10.3324/haematol.2015.141283.

  2. Kuter DJ, Bain B, Mufti G, Bagg A, Hasserjian RP. Bonemarrow fibrosis: Pathophysiology and clinical significanceof increased bone marrow stromal fibers. Br JHaematol 2007; 139 (3): 351-62. doi: 10.1111/j.1365-2141.2007.06807.x.

  3. Smith RA, Manassaram-Baptiste D, Brooks D, DoroshenkM, Fedewa S, Saslow D, et al. Cancer screening in theUnited States, 2015: A review of current AmericanCancer Society guidelines and current issues in cancerscreening. CA Cancer J Clin 2015; 65 (1): 30-54. doi:10.3322/caac.21261.

  4. Lee JJK, Park S, Park H, Kim S, Lee J, Lee J, et al. Tracingoncogene rearrangements in the mutational history oflung adenocarcinoma. Cell 2019; 177 (7): 1842-1857.e21.https://doi.org/10.1016/j.cell.2019.05.013

  5. Lang J, Zhao Q, He Y, Yu X. Bone turnover markers and novelbiomarkers in lung cancer bone metastases. Biomarkers2018; 23 (6): 518-26. doi: 10.1080/1354750X.2018.1463566.

  6. Goltzman D. Nonparathyroid hypercalcemia. Front HormRes 2018; 51: 77-90. doi: 10.1159/000491040.

  7. Chang WTW, Radin B, McCurdy MT. Calcium, magnesium,and phosphate abnormalities in the emergency department.Emerg Med Clin North Am 2014; 32 (2): 349-66.doi: 10.1016/j.emc.2013.12.006.

  8. Turner JJO. Hypercalcaemia - Presentation and management.Clin Med 2017; 17 (3): 270-3. https://doi.org/10.7861%2Fclinmedicine.17-3-270.

  9. Szymanski JJ, Otrock ZK, Patel KK, Scott MG. Incidence ofhumoral hypercalcemia of malignancy among hypercalcemicpatients with cancer. Clin Chim Acta 2016; 453: 190-3.http://dx.doi.org/10.1016/j.cca.2015.12.017.

  10. Goldner W. Cancer-related hypercalcemia. J Oncol Pract2016; 12 (5): 426-32. DOI: 10.1200/JOP.2016.011155

  11. Rosner MH, Dalkin AC. Onco-nephrology: The pathophysiologyand treatment of malignancy-associated hypercalcemia.Clin J Am Soc Nephrol 2012; 7 (10): 1722-9. doi:10.2215/CJN.02470312.

  12. Zagzag J, Hu MI, Fisher SB, Perrier ND. Hypercalcemia andcancer: Differential diagnosis and treatment. CA Cancer JClin 2018; 68 (5): 377-86. doi: 10.3322/caac.21489.

  13. Santarpia L, Koch CA, Sarlis NJ. Hypercalcemia in cancerpatients: Pathobiology and management. Horm MetabRes 2010; 42 (3): 153-64. doi: 10.1055/s-0029-1241821.

  14. Filho AGO, Carneiro BC, Pastore D, Silva IP, YamashitaSR, Consolo FD, et al. Whole-body imaging of multiplemyeloma: Diagnostic criteria. Radiographics 2019; 39 (4):1077-97. https://doi.org/10.1148/rg.2019180096.

  15. D’Oronzo S, Brown J, Coleman R. The role of biomarkersin the management of bone-homing malignancies. JBone Oncol 2017; 9: 1-9. http://dx.doi.org/10.1016/j.jbo.2017.09.001.

  16. Kang EJ, Lee SY, Kim HJ, Min KH, Hur GY, Shim JJ, et al.Prognostic factors and skeletal-related events in patientswith small cell lung cancer with bone metastases at thetime of diagnosis. Oncology 2016; 90 (2): 103-11. doi:10.1159/000442949.

  17. Ulas A, Bilici A, Durnali A, Tokluoglu S, Akinci S, Silay K, etal. Risk factors for skeletal-related events (SREs) and factorsaffecting SRE-free survival for nonsmall cell lung cancerpatients with bone metastases. Tumour Biol 2016; 37 (1):1131-40. doi: 10.1007/s13277-015-3907-z.

  18. Zhang L, Gong Z. Clinical characteristics and prognosticfactors in bone metastases from lung cancer. Med Sci Monit2017; 23: 4087-94. doi: 10.12659/msm.902971.

  19. Chambard L, Girard N, Ollier E, Rousseau JC, Duboeuf F,Carlier MC, et al. Bone, muscle, and metabolic parameterspredict survival in patients with synchronous bonemetastases from lung cancers. Bone 2018; 108: 202-9. doi:10.1016/j.bone.2018.01.004.




2020     |     www.medigraphic.com